Semaglutide may protect joints via muscle

A study published in iScience on 19 June 2026 reports that semaglutide may protect against osteoarthritis not only through weight loss but by acting directly on muscle mitochondria and reshaping glutamine metabolism^[1]. The research, conducted by a team at Shanghai Jiao Tong University, used cross-tissue single-cell RNA sequencing in mouse models to trace a previously unrecognised signalling pathway from muscle to cartilage.

What the researchers found

The team fed mice a high-fat diet to induce both obesity and osteoarthritis, then treated them with semaglutide. Using single-cell RNA sequencing across multiple tissues, they observed that the drug restored mitochondrial function in skeletal muscle cells that had been impaired by the high-fat diet^[1]. Multi-omics analysis (combining transcriptomic and metabolomic data) revealed that semaglutide reduced glutaminase activity in muscle, which in turn raised circulating glutamine levels.

Glutamine released from semaglutide-treated muscle cells then acted on chondrocytes (cartilage cells), reducing inflammatory markers and protecting against cartilage breakdown. The researchers confirmed this cross-tissue effect in vitro using C2C12 muscle cells and validated it in vivo with intramuscular mitochondrial transplantation experiments^[1]. The treated mice showed improvements in pain behaviour, cartilage integrity, muscle strength, and muscle fibre structure.

Why muscle-to-cartilage signalling matters

Most osteoarthritis research focuses on the joint itself: cartilage breakdown, synovial inflammation, subchondral bone remodelling. This study proposes that muscle tissue acts as a metabolic relay. When semaglutide fixes mitochondrial dysfunction in muscle, the downstream change in glutamine availability reduces inflammation in nearby cartilage. If confirmed in humans, this would mean the drug's benefit to osteoarthritis extends beyond mechanical unloading from weight loss to include a biochemical communication pathway between tissues.

Glutamine is the most abundant amino acid in the bloodstream and is already known to have anti-inflammatory properties in other contexts. What is new here is the claim that a GLP-1 receptor agonist can raise glutamine by acting on muscle mitochondria rather than by any direct effect on the joint. The researchers tested this by transplanting mitochondria from semaglutide-treated muscle into untreated mice and observing cartilage protection, a step that strengthens the causal argument^[1].

The idea that semaglutide has joint-protective effects independent of weight loss aligns with a separate line of evidence. A second preclinical study, published in Joint Bone Spine in May 2026, found that semaglutide reversed GAPDH downregulation in osteoarthritis chondrocytes, improved cell proliferation, and reduced inflammatory cytokine levels through a glycolysis-senescence-inflammation axis^[2]. Together, these papers suggest more than one mechanism through which the drug may slow cartilage degeneration.

Clinical evidence so far

On the clinical side, the STEP-9 trial published in the New England Journal of Medicine in October 2024 randomised 407 people with obesity and moderate-to-severe knee osteoarthritis to semaglutide 2.4 mg weekly or placebo^[3]. Over 68 weeks, the semaglutide group lost 13.7 percent of body weight (versus 3.2 percent on placebo) and reported a 41.7-point improvement on the WOMAC pain scale (versus 27.5 points on placebo). Both differences were statistically significant. STEP-9 was not designed to separate weight-related from weight-independent effects on joint pain, however.

A retrospective database analysis published in Regional Anesthesia and Pain Medicine in June 2026 examined adults with knee osteoarthritis and found that three years of exposure to newer GLP-1 receptor agonists (semaglutide or tirzepatide) was associated with a 4.71-percentage-point reduction in the eight-year risk of knee replacement surgery^[4]. The study used propensity score matching on cohorts of up to 42,062 participants, though as an observational analysis it cannot rule out unmeasured confounding.

What we do not yet know

The iScience study was conducted entirely in mice and cultured cells. Whether semaglutide produces the same mitochondrial and glutamine changes in human muscle tissue is unknown. Mouse models of osteoarthritis do not fully replicate the human disease, particularly for pain outcomes and the slow degenerative timescale. The dose and duration of semaglutide used in the animal model may not translate directly to the doses prescribed clinically for weight management or diabetes.

The mitochondrial transplantation experiment, while conceptually elegant, is an artificial intervention that would not be used therapeutically. It demonstrates a principle (that healthier mitochondria in muscle can protect cartilage) rather than a treatment pathway. Replicating the glutamine-mediated effect in a larger animal model, or demonstrating elevated circulating glutamine in human semaglutide users, would be a necessary next step.

It is also unclear whether the muscle-cartilage glutamine axis operates in joints other than the knee, or whether it is relevant in lean individuals with osteoarthritis who do not have diet-induced metabolic dysfunction. The STEP-9 pain improvements could still be largely weight-mediated, and no clinical trial has yet isolated a weight-independent mechanism in humans^[3].

Semaglutide is a prescription medicine approved for type 2 diabetes and chronic weight management. It is not approved for osteoarthritis. If you have joint pain, consult a healthcare provider about appropriate treatment options. This article is for educational purposes and does not constitute medical advice.